The markets opened lower with the Dow losing 14 points to 20,648 after an explosion killed ten people in a St. Petersburg metro station. Nasdaq held steady at 5,911.
On the upside
NovoCure (Nasdaq: NVCR) announced positive final results from a Phase 3 EF-14 trial adding Optune to standard temozolomide chemotherapy to treat newly diagnosed glioblastoma.
SteadyMed (Nasdaq: STDY) received a favorable ruling in the Inter Partes Review against a United Therapeutics patent.
Cyclacel Pharmaceuticals (Nasdaq: CYCC) reported upbeat preclinical data for CYC065 in inhibiting growth of lung cancer.
On the downside
DryShips (Nasdaq: DRYS) entered into a stock purchase agreement with Kalani Investments and entered into agreements to acquire six vessels for $268 million.
Investors locked in profits on Akari Therapeutics (Nasdaq: AKTX).
General Motors (NYSE: GM) reported a disappointing 2% increase in March sales.
In the broad market, declining issues outpaced advancers by a margin of nearly 7 to 5 on the NYSE and by more than 9 to 7 on Nasdaq. The broader S&P 500 index slipped 2 points to 2,360. Bitcoin soared $33 to $1123.
